azd-0837
Small moleculeexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00684307)
Timeline
Indications
Mechanism of action
- ThrombinINHIBITOR
F2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd0837
- azd0837
- azd0837
- azd 0837
- azd-0837
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00904800 | Phase 1 | May 1, 2009 | AstraZeneca, Medipolis Medical Research Institute, Kagoshima |
| NCT00878618 | Phase 1 | Apr 1, 2009 | AstraZeneca, IQVIA |
| NCT00812643 | Phase 1 | Jan 1, 2009 | AstraZeneca |
| NCT00812344 | Phase 1 | Dec 1, 2008 | AstraZeneca |
| NCT00623779 | Phase 2 | Oct 1, 2007 | AstraZeneca, University of Birmingham |
| NCT00645853 | Phase 2 | Oct 1, 2007 | Aarhus University, AstraZeneca |
| NCT00684307 | Phase 2 | Feb 1, 2007 | AstraZeneca, University of Birmingham |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 7 | 7 | 2 | 2007 |
| University of Birmingham | Academic/Hospital | 2 | 0 | 1 | 2007 |
| Aarhus University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| IQVIA | For profit | 1 | 0 | 1 | 2009 |
| Medipolis Medical Research Institute, Kagoshima | Academic/Hospital | 1 | 0 | 1 | 2009 |
5 organizations
Page 1 / 1